Payment overview · 2025
General Payments
$949.96
51 reported records · 13 companies
Healthcare provider profile · identity verified
Steven T Overby, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GERMANTOWN, TN · NPI 1194726679
Verified facts
What the public records show
CMS Open Payments records show Steven T Overby, MD received $949.96 in general payments during 2025 across 51 reported records.
Novo Nordisk Inc accounted for 39.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rybelsus, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 217 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $372.34 | 39.2% | 18 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $142.85 | 15.0% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $85.85 | 9.0% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $68.07 | 7.2% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $53.93 | 5.7% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.60 | 5.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $47.20 | 5.0% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.98 | 3.2% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $29.70 | 3.1% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $24.20 | 2.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.47 | 1.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.32 | 1.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.45 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $949.96 | 51 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $213.88 | 9 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $132.07 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $113.11 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $111.43 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $95.70 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $85.85 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $85.85 | 6 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $68.07 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $53.93 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $47.60 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $47.20 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $29.98 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $29.70 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $29.70 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $24.20 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.47 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.45 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.45 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.45 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $10.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 217 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 152 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 82 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
137 | 37 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
217 | 48 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
152 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
89 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
82 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
123 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
26 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 649 | 181 |
| Atorvastatin Calcium | Atorvastatin Calcium | 563 | 167 |
| Amlodipine Besylate | Amlodipine Besylate | 463 | 132 |
| Montelukast Sodium | Montelukast Sodium | 392 | 111 |
| Carvedilol | Carvedilol | 391 | 109 |
| Gabapentin | Gabapentin | 371 | 94 |
| Irbesartan | Irbesartan | 332 | 87 |
| Alprazolam | Alprazolam | 315 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 311 | 96 |
| Omeprazole | Omeprazole | 287 | 90 |
| Famotidine | Famotidine | 281 | 90 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 256 | 79 |
| Losartan Potassium | Losartan Potassium | 249 | 77 |
| Tamsulosin Hcl | Tamsulosin Hcl | 246 | 73 |
| Simvastatin | Simvastatin | 238 | 73 |
| Duloxetine Hcl | Duloxetine Hcl | 220 | 51 |
| Jardiance | Empagliflozin | 217 | 48 |
| Metformin Hcl Er | Metformin Hcl | 212 | 63 |
| Zolpidem Tartrate | Zolpidem Tartrate | 211 | 50 |
| Lisinopril | Lisinopril | 210 | 61 |
| Escitalopram Oxalate | Escitalopram Oxalate | 199 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 197 | 60 |
| Pravastatin Sodium | Pravastatin Sodium | 191 | 55 |
| Trazodone Hcl | Trazodone Hcl | 181 | 61 |
| Tramadol Hcl | Tramadol Hcl | 179 | 44 |
| Potassium Chloride | Potassium Chloride | 173 | 49 |
| Meloxicam | Meloxicam | 170 | 67 |
| Clonazepam | Clonazepam | 166 | 33 |
| Sertraline Hcl | Sertraline Hcl | 156 | 50 |
| Chlorthalidone | Chlorthalidone | 153 | 50 |
| Mounjaro | Tirzepatide | 152 | 26 |
| Spironolactone | Spironolactone | 152 | 46 |
| Allopurinol | Allopurinol | 151 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 148 | 40 |
| Tizanidine Hcl | Tizanidine Hcl | 145 | 35 |
| Synthroid | Levothyroxine Sodium | 137 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 126 | 43 |
| Eliquis | Apixaban | 123 | 38 |
| Ezetimibe | Ezetimibe | 122 | 37 |
| Furosemide | Furosemide | 122 | 39 |
| Liothyronine Sodium | Liothyronine Sodium | 122 | 29 |
| Celecoxib | Celecoxib | 119 | 39 |
| Januvia | Sitagliptin Phosphate | 118 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 115 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 113 | 22 |
| Valsartan | Valsartan | 111 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 36 |
| Telmisartan | Telmisartan | 95 | 23 |
| Glimepiride | Glimepiride | 94 | 27 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 93 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 90 | 25 |
| Baclofen | Baclofen | 89 | 41 |
| Doxycycline Hyclate | Doxycycline Hyclate | 89 | 77 |
| Trulicity | Dulaglutide | 89 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 89 | 19 |
| Methylprednisolone | Methylprednisolone | 88 | 67 |
| Finasteride | Finasteride | 87 | 28 |
| Buspirone Hcl | Buspirone Hcl | 85 | 30 |
| Ozempic | Semaglutide | 82 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 81 | 32 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 77 | 77 |
| Temazepam | Temazepam | 67 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 66 | 57 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 66 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 65 | 31 |
| Xarelto | Rivaroxaban | 65 | 19 |
| Nystatin | Nystatin | 64 | 31 |
| Raloxifene Hcl | Raloxifene Hcl | 64 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 59 | 11 |
| Eszopiclone | Eszopiclone | 58 | suppressed |
| Myrbetriq | Mirabegron | 57 | 16 |
| Fluconazole | Fluconazole | 55 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 55 | 16 |
| Solifenacin Succinate | Solifenacin Succinate | 55 | 16 |
| Doxepin Hcl | Doxepin Hcl | 54 | 22 |
| Cefdinir | Cefdinir | 53 | 49 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 53 | suppressed |
| Metformin Hcl | Metformin Hcl | 51 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 20 |
| Memantine Hcl | Memantine Hcl | 50 | 12 |
| Mupirocin | Mupirocin | 50 | 40 |
| Pioglitazone Hcl | Pioglitazone Hcl | 50 | 13 |
| Ramipril | Ramipril | 49 | 13 |
| Topiramate | Topiramate | 49 | 13 |
| Fenofibrate | Fenofibrate | 48 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 45 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 45 | 12 |
| Nateglinide | Nateglinide | 45 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 45 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | 17 |
| Lorazepam | Lorazepam | 44 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 44 | 22 |
| Azelastine Hcl | Azelastine Hcl | 43 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 37 |
| Methocarbamol | Methocarbamol | 43 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 43 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 13 |
| Lovastatin | Lovastatin | 42 | 13 |
| Aripiprazole | Aripiprazole | 39 | 12 |
| Candesartan Cilexetil | Candesartan Cilexetil | 39 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | 13 |
| Promethazine Hcl | Promethazine Hcl | 39 | suppressed |
| Prednisone | Prednisone | 38 | 16 |
| Benazepril Hcl | Benazepril Hcl | 37 | 12 |
| Febuxostat | Febuxostat | 36 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 36 | 16 |
| Pregabalin | Pregabalin | 36 | 11 |
| Mirtazapine | Mirtazapine | 35 | suppressed |
| Ketoconazole | Ketoconazole | 34 | 26 |
| Azithromycin | Azithromycin | 33 | 28 |
| Amoxicillin | Amoxicillin | 32 | 25 |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Lactulose | Lactulose | 32 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 30 | suppressed |
| Colchicine | Colchicine | 29 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Calcitriol | Calcitriol | 28 | suppressed |
| Estradiol | Estradiol | 28 | 16 |
| Atenolol | Atenolol | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Cephalexin | Cephalexin | 27 | 17 |
| Colestipol Hcl | Colestipol Hcl | 27 | 11 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 27 | 21 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 26 |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 26 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 15 |
| Dutasteride | Dutasteride | 20 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Felodipine Er | Felodipine | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 12 |
| Acyclovir | Acyclovir | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Eplerenone | Eplerenone | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 15 |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Nisoldipine | Nisoldipine | 17 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 15 | 12 |
| Sucralfate | Sucralfate | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Trimethoprim | Trimethoprim | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 13 | 13 |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 13 | suppressed |
| Dexilant | Dexlansoprazole | 13 | suppressed |
| Minoxidil | Minoxidil | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Wegovy | Semaglutide | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $949.96 · 51 records | Novo Nordisk Inc | ABRYSVO, BREZTRI, COMIRNATY, FREESTYLE LIBRE 3, Fluad, Flucelvax, GEMTESA, INJECTAFER, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, OTEZLA, Ozempic, PREVNAR 20, REPATHA, Rybelsus, VOQUEZNA, VRAYLAR, Wegovy, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error